BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sathekge MM, Ankrah AO, Lawal I, Vorster M. Monitoring Response to Therapy. Semin Nucl Med 2018;48:166-81. [PMID: 29452619 DOI: 10.1053/j.semnuclmed.2017.10.004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 4.6] [Reference Citation Analysis]
Number Citing Articles
1 Ankrah AO, Sathekge MM, Dierckx RAJO, Glaudemans AWJM. Radionuclide Imaging of Fungal Infections and Correlation with the Host Defense Response. J Fungi (Basel) 2021;7:407. [PMID: 34067410 DOI: 10.3390/jof7060407] [Reference Citation Analysis]
2 More S, Marakalala MJ, Sathekge M. Tuberculosis: Role of Nuclear Medicine and Molecular Imaging With Potential Impact of Neutrophil-Specific Tracers. Front Med 2021;8:758636. [DOI: 10.3389/fmed.2021.758636] [Reference Citation Analysis]
3 Tamgue O, Mezajou CF, Ngongang NN, Kameni C, Ngum JA, Simo USF, Tatang FJ, Akami M, Ngono AN. Non-Coding RNAs in the Etiology and Control of Major and Neglected Human Tropical Diseases. Front Immunol 2021;12:703936. [PMID: 34737736 DOI: 10.3389/fimmu.2021.703936] [Reference Citation Analysis]
4 Ankrah AO, Span LFR, Klein HC, de Jong PA, Dierckx RAJO, Kwee TC, Sathekge MM, Glaudemans AWJM. Role of FDG PET/CT in monitoring treatment response in patients with invasive fungal infections. Eur J Nucl Med Mol Imaging 2019;46:174-83. [PMID: 30343434 DOI: 10.1007/s00259-018-4192-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
5 Lawal IO, Fourie BP, Mathebula M, Moagi I, Lengana T, Moeketsi N, Nchabeleng M, Hatherill M, Sathekge MM. 18F-FDG PET/CT as a Noninvasive Biomarker for Assessing Adequacy of Treatment and Predicting Relapse in Patients Treated for Pulmonary Tuberculosis. J Nucl Med 2020;61:412-7. [PMID: 31451489 DOI: 10.2967/jnumed.119.233783] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
6 Prevet H, Collins I. Labelled chemical probes for demonstrating direct target engagement in living systems. Future Medicinal Chemistry 2019;11:1195-224. [DOI: 10.4155/fmc-2018-0370] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
7 Wang L, Wen Z, Ma H, Wu L, Chen H, Zhu Y, Niu L, Wu Q, Li H, Shi L, Li L, Wan L, Wang J, Wong KW, Song Y. Long non-coding RNAs ENST00000429730.1 and MSTRG.93125.4 are associated with metabolic activity in tuberculosis lesions of sputum-negative tuberculosis patients. Aging (Albany NY) 2021;13:8228-47. [PMID: 33686954 DOI: 10.18632/aging.202634] [Reference Citation Analysis]
8 Boudabbous S, Paulin EN, Delattre BMA, Hamard M, Vargas MI. Spinal disorders mimicking infection. Insights Imaging 2021;12:176. [PMID: 34862958 DOI: 10.1186/s13244-021-01103-5] [Reference Citation Analysis]
9 Lawal IO, Stoltz AC, Sathekge MM. Molecular imaging of cardiovascular inflammation and infection in people living with HIV infection. Clin Transl Imaging 2020;8:141-55. [DOI: 10.1007/s40336-020-00370-4] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Treglia G, Pascale M, Lazzeri E, van der Bruggen W, Delgado Bolton RC, Glaudemans AWJM. Diagnostic performance of 18F-FDG PET/CT in patients with spinal infection: a systematic review and a bivariate meta-analysis. Eur J Nucl Med Mol Imaging 2020;47:1287-301. [PMID: 31729539 DOI: 10.1007/s00259-019-04571-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
11 Zandifar A, Saucedo J, Vossough A, Alavi A, Hunt SJ. Role of Fluorodeoxyglucose-PET in Interventional Radiology. PET Clin 2022:S1556-8598(22)00008-6. [PMID: 35662495 DOI: 10.1016/j.cpet.2022.03.003] [Reference Citation Analysis]
12 Yu WY, Lu PX, Assadi M, Huang XL, Skrahin A, Rosenthal A, Gabrielian A, Tartakovsky M, Wáng YXJ. Updates on 18F-FDG-PET/CT as a clinical tool for tuberculosis evaluation and therapeutic monitoring. Quant Imaging Med Surg 2019;9:1132-46. [PMID: 31367568 DOI: 10.21037/qims.2019.05.24] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
13 Treglia G. Diagnostic Performance of 18F-FDG PET/CT in Infectious and Inflammatory Diseases according to Published Meta-Analyses. Contrast Media Mol Imaging. 2019;2019:3018349. [PMID: 31427907 DOI: 10.1155/2019/3018349] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 11.3] [Reference Citation Analysis]
14 Larsen MH, Lacourciere K, Parker TM, Kraigsley A, Achkar JM, Adams LB, Dupnik KM, Hall-Stoodley L, Hartman T, Kanipe C, Kurtz SL, Miller MA, Salvador LCM, Spencer JS, Robinson RT. The Many Hosts of Mycobacteria 8 (MHM8): A conference report. Tuberculosis (Edinb) 2020;121:101914. [PMID: 32279870 DOI: 10.1016/j.tube.2020.101914] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Ankrah AO, Creemers-Schild D, de Keizer B, Klein HC, Dierckx RAJO, Kwee TC, Span LFR, de Jong PA, Sathekge MM, Glaudemans AWJM. The Added Value of [18F]FDG PET/CT in the Management of Invasive Fungal Infections. Diagnostics (Basel) 2021;11:137. [PMID: 33477267 DOI: 10.3390/diagnostics11010137] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
16 Tian Y, Zhang Y, Wen B, Li C, He Y. Hepatosplenic tuberculosis on 18F-FDG PET/CT imaging in a patient with pyrexia of unknown origin. Rev Esp Med Nucl Imagen Mol 2021;40:267-9. [PMID: 33903087 DOI: 10.1016/j.remn.2020.05.004] [Reference Citation Analysis]
17 Jin X, Huo L, Wang T, Liu Y, Li F. Hepatosplenic Tuberculosis on Pretherapy and Posttherapy FDG PET/CT. Clin Nucl Med 2020;45:174-6. [DOI: 10.1097/rlu.0000000000002858] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
18 Malherbe ST, Dupont P, Kant I, Ahlers P, Kriel M, Loxton AG, Chen RY, Via LE, Thienemann F, Wilkinson RJ, Barry CE 3rd, Griffith-Richards S, Ellman A, Ronacher K, Winter J, Walzl G, Warwick JM; Catalysis Biomarker Consortium. A semi-automatic technique to quantify complex tuberculous lung lesions on 18F-fluorodeoxyglucose positron emission tomography/computerised tomography images. EJNMMI Res 2018;8:55. [PMID: 29943161 DOI: 10.1186/s13550-018-0411-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
19 Palestro CJ. Letter from the Guest Editor. Semin Nucl Med 2018;48:84-5. [PMID: 29452622 DOI: 10.1053/j.semnuclmed.2017.11.005] [Reference Citation Analysis]
20 Lawal IO, Mokoala KMG, Kgatle MM, Dierckx RAJO, Glaudemans AWJM, Sathekge MM, Ankrah AO. Radionuclide Imaging of Invasive Fungal Disease in Immunocompromised Hosts. Diagnostics (Basel) 2021;11:2057. [PMID: 34829403 DOI: 10.3390/diagnostics11112057] [Reference Citation Analysis]
21 Tian Y, Zhang Y, Wen B, Li C, He Y. Hepatosplenic tuberculosis on 18F-FDG PET/CT imaging in a patient with Pyrexia of Unknown Origin. Rev Esp Med Nucl Imagen Mol (Engl Ed) 2021;40:267-9. [PMID: 34218896 DOI: 10.1016/j.remnie.2020.06.001] [Reference Citation Analysis]
22 Lawal IO, Mokoala KMG, Mathebula M, Moagi I, Popoola GO, Moeketsi N, Nchabeleng M, Hikuam C, Ellner JJ, Hatherill M, Fourie BP, Sathekge MM. Correlation Between CT Features of Active Tuberculosis and Residual Metabolic Activity on End-of-Treatment FDG PET/CT in Patients Treated for Pulmonary Tuberculosis. Front Med (Lausanne) 2022;9:791653. [PMID: 35295606 DOI: 10.3389/fmed.2022.791653] [Reference Citation Analysis]
23 Palestro CJ. Molecular Imaging of Infection: The First 50 Years. Semin Nucl Med 2020;50:23-34. [PMID: 31843059 DOI: 10.1053/j.semnuclmed.2019.10.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]